On Monday, Neumora Therapeutics Inc (NASDAQ: NMRA) was 6.19% up from the session before settling in for the closing price of $1.13. A 52-week range for NMRA has been $1.12 – $17.19.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
When this article was written, the company’s average yearly earnings per share was at 4.29%. With a float of $56.00 million, this company’s outstanding shares have now reached $161.71 million.
Let’s determine the extent of company efficiency that accounts for 110 employees. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Neumora Therapeutics Inc (NMRA) Insider Activity
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Neumora Therapeutics Inc stocks. The insider ownership of Neumora Therapeutics Inc is 65.43%, while institutional ownership is 37.28%. The most recent insider transaction that took place on Mar 12 ’25, was worth 21,450. Before that another transaction happened on Feb 18 ’25, when Company’s insider sold 13,871 for $1.69, making the entire transaction worth $23,468. This insider now owns 7,405,004 shares in total.
Neumora Therapeutics Inc (NMRA) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.4 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 4.29% per share during the next fiscal year.
Neumora Therapeutics Inc (NASDAQ: NMRA) Trading Performance Indicators
You can see what Neumora Therapeutics Inc (NMRA) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 10.51.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.53, a number that is poised to hit -0.38 in the next quarter and is forecasted to reach -1.23 in one year’s time.
Technical Analysis of Neumora Therapeutics Inc (NMRA)
Looking closely at Neumora Therapeutics Inc (NASDAQ: NMRA), its last 5-days average volume was 1.2 million, which is a drop from its year-to-date volume of 3.53 million. As of the previous 9 days, the stock’s Stochastic %D was 12.01%. Additionally, its Average True Range was 0.14.
During the past 100 days, Neumora Therapeutics Inc’s (NMRA) raw stochastic average was set at 0.66%, which indicates a significant decrease from 20.03% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 87.47% in the past 14 days, which was lower than the 275.91% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.7160, while its 200-day Moving Average is $8.8681. However, in the short run, Neumora Therapeutics Inc’s stock first resistance to watch stands at $1.2367. Second resistance stands at $1.2733. The third major resistance level sits at $1.3267. If the price goes on to break the first support level at $1.1467, it is likely to go to the next support level at $1.0933. Should the price break the second support level, the third support level stands at $1.0567.
Neumora Therapeutics Inc (NASDAQ: NMRA) Key Stats
There are 161,979K outstanding shares of the company, which has a market capitalization of 194.38 million. As of now, sales total 0 K while income totals -243,790 K. Its latest quarter income was 0 K while its last quarter net income were -58,820 K.
